3.18
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
What analysts say about Compass Therapeutics Inc. stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
Stifel Keeps Buy Rating on Compass Therapeutics (CMPX) - Insider Monkey
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Compass Therapeutics Inc. Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Compass Therapeutics (CMPX) Gains Analyst Confidence with Promising Cancer Pipeline - MSN
Compass Therapeutics (CMPX) Soars 8.47% on Analyst Endorsement - AInvest
What drives Compass Therapeutics Inc. stock priceFree Stock Market Trend Analysis - jammulinksnews.com
I meant for Compass Therapeutics, Inc. - AInvest
Is Compass Therapeutics Inc. a good long term investmentRemarkable growth - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Compass Therapeutics Inc. stock a growth or value playHigh Return Setup Scanner - beatles.ru
What analysts say about Compass Therapeutics Inc. stock outlookFree Real-Time Market Predictions - beatles.ru
What makes Compass Therapeutics Inc. stock price move sharply10x Return With Managed Risk - Newser
Why Compass Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
How Axsome Therapeutics Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
How Compass Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target - Investing.com Canada
Contrasting Compass Therapeutics (NASDAQ:CMPX) & Generation Bio (NASDAQ:GBIO) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages - Defense World
Compass Therapeutics (CMPX) soars 4.01% on FDA Fast Track Designation - AInvest
Vontobel Holding Ltd. Invests $57,000 in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Raises Target Price to $24 - 富途牛牛
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Earn Buy Rating - AInvest
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial - Defense World
H.C. Wainwright Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics, Inc.(NasdaqCM: CMPX) added to Russell 3000E Growth Index - MarketScreener
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer - TipRanks
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Benzinga
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):